{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:21:35Z","timestamp":1784305295482,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study compared the survival outcomes after thermal ablation versus wedge resection in patients with stage I non-small cell lung cancer (NSCLC)\u2009\u2264\u20092\u00a0cm.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from the United States (US) National Cancer Institute Surveillance Epidemiology and End Results (SEER) database from 2004 to 2019 were retrospectively analyzed. Patients with stage I NSCLC and lesions\u2009\u2264\u20092\u00a0cm who received thermal ablation or wedge resection were included. Patients who received chemotherapy or radiotherapy were excluded. Propensity-score matching (PSM) was applied to balance the baseline characteristics between patients who underwent the two procedures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Univariate and Cox regression analyses were performed to determine the associations between study variables, overall survival (OS), and cancer-specific survival (CSS). After PSM, 328 patients remained for analysis. Multivariable Cox regression analysis revealed, compared to wedge resection, thermal ablation was significantly associated with a greater risk of poor OS (adjusted HR [aHR]: 1.34, 95% CI: 1.09\u20131.63, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) but not CSS (aHR: 1.28, 95% CI: 0.96\u20131.71, <jats:italic>p<\/jats:italic>\u2009=\u20090.094). In stratified analyses, no significant differences were observed with respect to OS and CSS between the two procedures regardless of histology and grade. In patients with tumor size 1 to 2\u00a0cm, compared to wedge resection, thermal ablation was significantly associated with a higher risk of poor OS (aHR: 1.35, 95% CI: 1.10\u20131.66, <jats:italic>p<\/jats:italic>\u2009=\u20090.004). In contrast, no significant difference was found on OS and CSS between thermal ablation and wedge resection among those with tumor size\u2009&lt;\u20091\u00a0cm.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with stage I NSCLC and tumor size\u2009&lt;\u20091\u00a0cm, thermal ablation has similar OS and CSS with wedge resection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40644-024-00733-4","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T08:03:33Z","timestamp":1720685013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Survival after thermal ablation versus wedge resection for stage I non-small cell lung cancer\u2009&lt;\u20091\u00a0cm and 1 to 2\u00a0cm: evidence from the US SEER database"],"prefix":"10.1186","volume":"24","author":[{"given":"Shelly","family":"Yim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Chan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Sen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Hong","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"1","key":"733_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/wo.2021.103829","volume":"25","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25(1):45\u201352. https:\/\/doi.org\/10.5114\/wo.2021.103829","journal-title":"Contemp Oncol (Pozn)"},{"issue":"7689","key":"733_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354. https:\/\/doi.org\/10.1038\/nature25183","journal-title":"Nature"},{"issue":"1","key":"733_CR3","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1038\/s41598-021-86203-4","volume":"11","author":"J Shi","year":"2021","unstructured":"Shi J, Li D, Liang D, He Y. Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China. Sci Rep. 2021;11(1):6817. https:\/\/doi.org\/10.1038\/s41598-021-86203-4","journal-title":"Sci Rep"},{"issue":"1","key":"733_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","volume":"10","author":"A Casal-Mouri\u00f1o","year":"2021","unstructured":"Casal-Mouri\u00f1o A, Ruano-Ravina A, Lorenzo-Gonz\u00e1lez M, Rodr\u00edguez-Mart\u00ednez \u00c1, Giraldo-Osorio A, Varela-Lema L, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506\u201318. https:\/\/doi.org\/10.21037\/tlcr.2020.03.40","journal-title":"Transl Lung Cancer Res"},{"issue":"71","key":"733_CR5","first-page":"287","volume":"13","author":"P Saintigny","year":"2012","unstructured":"Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012;13(71):287\u201397.","journal-title":"Discov Med"},{"issue":"2","key":"733_CR6","doi-asserted-by":"publisher","first-page":"e190058","DOI":"10.1148\/rycan.2020190058","volume":"2","author":"DS Gierada","year":"2020","unstructured":"Gierada DS, Black WC, Chiles C, Pinsky PF, Yankelevitz DF. Low-dose CT screening for Lung Cancer: evidence from 2 decades of study. Radiol Imaging Cancer. 2020;2(2):e190058. https:\/\/doi.org\/10.1148\/rycan.2020190058","journal-title":"Radiol Imaging Cancer"},{"issue":"suppl4","key":"733_CR7","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","volume":"28","author":"PE Postmus","year":"2017","unstructured":"Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl4):iv1\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdx222","journal-title":"Ann Oncol"},{"issue":"8","key":"733_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345\u201356. https:\/\/doi.org\/10.1038\/s41591-021-01450-2","journal-title":"Nat Med"},{"issue":"9","key":"733_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11864-020-00759-3","volume":"21","author":"M Alexander","year":"2020","unstructured":"Alexander M, Lin E, Cheng H. Leptomeningeal metastases in Non-small Cell Lung Cancer: optimal systemic management in NSCLC with and without driver mutations. Curr Treat Options Oncol. 2020;21(9):72. https:\/\/doi.org\/10.1007\/s11864-020-00759-3","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"733_CR10","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1245\/s10434-021-10857-7","volume":"29","author":"Y Shi","year":"2022","unstructured":"Shi Y, Wu S, Ma S, Lyu Y, Xu H, Deng L, et al. Comparison between Wedge Resection and Lobectomy\/Segmentectomy for Early-Stage Non-small Cell Lung Cancer: a bayesian Meta-analysis and systematic review. Ann Surg Oncol. 2022;29(3):1868\u201379. https:\/\/doi.org\/10.1245\/s10434-021-10857-7","journal-title":"Ann Surg Oncol"},{"key":"733_CR11","doi-asserted-by":"publisher","unstructured":"Song C, Lu Z, Li D, Pan S, Li N, Geng Q. Survival after wedge resection versus lobectomy for stage IA second primary NSCLC with previous lung cancer-directed surgery. Front Oncol. 2022;12(890033). https:\/\/doi.org\/10.3389\/fonc.2022.890033","DOI":"10.3389\/fonc.2022.890033"},{"key":"733_CR12","doi-asserted-by":"publisher","unstructured":"Wang P, Wang S, Liu Z, Sui X, Wang X, Li X, et al. Segmentectomy and Wedge Resection for Elderly patients with Stage I Non-small Cell Lung Cancer: a systematic review and Meta-analysis. J Clin Med. 2022;11(2). https:\/\/doi.org\/10.3390\/jcm11020294","DOI":"10.3390\/jcm11020294"},{"issue":"1","key":"733_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13019-021-01568-x","volume":"16","author":"L Wu","year":"2021","unstructured":"Wu L, Zhao W, Chen T, Yang Y. Surgical choice for patients with stage I non-small-cell lung cancer\u2009\u2264\u20092\u00a0cm: an analysis from surveillance, epidemiology, and end results database. J Cardiothorac Surg. 2021;16(1):191. https:\/\/doi.org\/10.1186\/s13019-021-01568-x","journal-title":"J Cardiothorac Surg"},{"issue":"10","key":"733_CR14","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.21037\/jtd.2017.08.142","volume":"9","author":"CK Narsule","year":"2017","unstructured":"Narsule CK, Sridhar P, Nair D, Gupta A, Oommen RG, Ebright MI, et al. Percutaneous thermal ablation for stage IA non-small cell lung cancer: long-term follow-up. J Thorac Dis. 2017;9(10):4039\u201345. https:\/\/doi.org\/10.21037\/jtd.2017.08.142","journal-title":"J Thorac Dis"},{"issue":"10","key":"733_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.diii.2016.08.016","volume":"97","author":"T de Baere","year":"2016","unstructured":"de Baere T, Tselikas L, Catena V, Buy X, Deschamps F, Palussi\u00e8re J. Percutaneous thermal ablation of primary lung cancer. Diagn Interv Imaging. 2016;97(10):1019\u201324. https:\/\/doi.org\/10.1016\/j.diii.2016.08.016","journal-title":"Diagn Interv Imaging"},{"key":"733_CR16","doi-asserted-by":"publisher","unstructured":"Zeng C, Lu J, Tian Y, Fu X. Thermal ablation Versus Wedge Resection for Stage I non-small cell Lung Cancer based on the Eighth Edition of the TNM classification: a Population Study of the US SEER database. Front Oncol. 2020;10(571684). https:\/\/doi.org\/10.3389\/fonc.2020.571684","DOI":"10.3389\/fonc.2020.571684"},{"issue":"6","key":"733_CR17","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/ijc.30548","volume":"140","author":"DL Goldwasser","year":"2017","unstructured":"Goldwasser DL. Estimation of the tumor size at cure threshold among aggressive non-small cell lung cancers (NSCLCs): evidence from the surveillance, epidemiology, and end results (SEER) program and the national lung screening trial (NLST). Int J Cancer. 2017;140(6):1280\u201392. https:\/\/doi.org\/10.1002\/ijc.30548","journal-title":"Int J Cancer"},{"issue":"5","key":"733_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.canep.2009.10.007","volume":"33","author":"AP Polednak","year":"2009","unstructured":"Polednak AP. Lung cancer incidence trends by histologic type in areas of California vs. other areas in the Surveillance, Epidemiology and End results Program. Cancer Epidemiol. 2009;33(5):319\u201324. https:\/\/doi.org\/10.1016\/j.canep.2009.10.007","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"733_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3978\/j.issn.2218-6751.2014.06.11","volume":"3","author":"H Sakurai","year":"2014","unstructured":"Sakurai H, Asamura H. Sublobar resection for early-stage lung cancer. Transl Lung Cancer Res. 2014;3(3):164\u201372. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2014.06.11","journal-title":"Transl Lung Cancer Res"},{"key":"733_CR20","doi-asserted-by":"publisher","unstructured":"Lei X, Zhou N, Zhang H, Li T, Ren F, Zhang B, et al. Lobe-Specific Analysis of Sublobar Lung Resection for NSCLC Patients with Tumors\u2009\u2264\u20092\u00a0cm. Cancers (Basel). 2022;14(13). https:\/\/doi.org\/10.3390\/cancers14133265","DOI":"10.3390\/cancers14133265"},{"issue":"6","key":"733_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJMoa2212083","volume":"388","author":"N Altorki","year":"2023","unstructured":"Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-small-cell Lung Cancer. N Engl J Med. 2023;388(6):489\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2212083","journal-title":"N Engl J Med"},{"issue":"3","key":"733_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.suc.2022.01.006","volume":"102","author":"CM Godfrey","year":"2022","unstructured":"Godfrey CM, Marmor HN, Lambright ES, Grogan EL. Minimally invasive and Sublobar resections for Lung Cancer. Surg Clin North Am. 2022;102(3):483\u201392. https:\/\/doi.org\/10.1016\/j.suc.2022.01.006","journal-title":"Surg Clin North Am"},{"issue":"3","key":"733_CR23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jtcvs.2019.03.090","volume":"158","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Saji H, Aokage K, Watanabe SI, Okada M, Mizusawa J, et al. Comparison of pulmonary segmentectomy and lobectomy: safety results of a randomized trial. J Thorac Cardiovasc Surg. 2019;158(3):895\u2013907. https:\/\/doi.org\/10.1016\/j.jtcvs.2019.03.090","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"9","key":"733_CR24","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ejso.2016.04.063","volume":"42","author":"G Hamilton","year":"2016","unstructured":"Hamilton G, Rath B, Ulsperger E. A review of the role of surgery for small cell lung cancer and the potential prognostic value of enumeration of circulating tumor cells. Eur J Surg Oncol. 2016;42(9):1296\u2013302. https:\/\/doi.org\/10.1016\/j.ejso.2016.04.063","journal-title":"Eur J Surg Oncol"},{"key":"733_CR25","doi-asserted-by":"publisher","unstructured":"Benet J, Toffart AC, Brichon PY, Chollier T, Ruckly S, Villa J, et al. Survival of clinical stage III NSCLC according to therapeutic strategy: relevance of the tumor board decision in the era of immunotherapy. Cancer Treat Res Commun. 2022;30(100508). https:\/\/doi.org\/10.1016\/j.ctarc.2021.100508","DOI":"10.1016\/j.ctarc.2021.100508"},{"issue":"3","key":"733_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/1759-7714.13795","volume":"12","author":"F Kong","year":"2021","unstructured":"Kong F, Wang C, Li Y, Li X. Advances in study of the sequence of lung tumor biopsy and thermal ablation. Thorac Cancer. 2021;12(3):279\u201386. https:\/\/doi.org\/10.1111\/1759-7714.13795","journal-title":"Thorac Cancer"},{"issue":"2","key":"733_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1055\/s-0034-1373786","volume":"31","author":"CA Ridge","year":"2014","unstructured":"Ridge CA, Solomon SB, Thornton RH. Thermal ablation of stage I non-small cell lung carcinoma. Semin Intervent Radiol. 2014;31(2):118\u201324. https:\/\/doi.org\/10.1055\/s-0034-1373786","journal-title":"Semin Intervent Radiol"},{"key":"733_CR28","doi-asserted-by":"publisher","unstructured":"Ghosn M, Solomon SB. Current management of Oligometastatic Lung Cancer and Future perspectives: results of thermal ablation as a local ablative therapy. Cancers (Basel). 2021;13(20). https:\/\/doi.org\/10.3390\/cancers13205202","DOI":"10.3390\/cancers13205202"},{"issue":"1","key":"733_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13019-022-01766-1","volume":"17","author":"Y Li","year":"2022","unstructured":"Li Y, Yang F, Huang YY, Wang T. Sublobar resection versus ablation for stage I non-small-cell lung cancer: a meta-analysis. J Cardiothorac Surg. 2022;17(1):17. https:\/\/doi.org\/10.1186\/s13019-022-01766-1","journal-title":"J Cardiothorac Surg"},{"issue":"1","key":"733_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s13019-022-02090-4","volume":"17","author":"R Liu","year":"2022","unstructured":"Liu R, Shen Q, Lu H. The efficacy and safety of thermal ablation for patients with lung malignancy: a meta-analysis of 12 studies in China. J Cardiothorac Surg. 2022;17(1):334. https:\/\/doi.org\/10.1186\/s13019-022-02090-4","journal-title":"J Cardiothorac Surg"},{"issue":"6","key":"733_CR31","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.21037\/tlcr-20-1075","volume":"10","author":"K Rangamuwa","year":"2021","unstructured":"Rangamuwa K, Leong T, Weeden C, Asselin-Labat ML, Bozinovski S, Christie M, et al. Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Transl Lung Cancer Res. 2021;10(6):2842\u201357. https:\/\/doi.org\/10.21037\/tlcr-20-1075","journal-title":"Transl Lung Cancer Res"},{"issue":"14","key":"733_CR32","doi-asserted-by":"publisher","first-page":"11722","DOI":"10.18632\/oncotarget.24270","volume":"9","author":"T Streitparth","year":"2018","unstructured":"Streitparth T, Schumacher D, Damm R, Friebe B, Mohnike K, Kosiek O, et al. Percutaneous radiofrequency ablation in the treatment of pulmonary malignancies: efficacy, safety and predictive factors. Oncotarget. 2018;9(14):11722\u201333. https:\/\/doi.org\/10.18632\/oncotarget.24270","journal-title":"Oncotarget"},{"issue":"7","key":"733_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11912-021-01072-4","volume":"23","author":"J Palussi\u00e8re","year":"2021","unstructured":"Palussi\u00e8re J, Cazayus M, Cousin S, Cabart M, Chomy F, Catena V, et al. Is there a role for percutaneous ablation for early stage Lung Cancer? What is the evidence? Curr Oncol Rep. 2021;23(7):81. https:\/\/doi.org\/10.1007\/s11912-021-01072-4","journal-title":"Curr Oncol Rep"},{"key":"733_CR34","doi-asserted-by":"publisher","unstructured":"Huang BY, Li XM, Song XY, Zhou JJ, Shao Z, Yu ZQ et al. Long-term results of CT-guided percutaneous radiofrequency ablation of inoperable patients with stage Ia non-small cell lung cancer: A retrospective cohort study. Int J Surg. 2018; 53(143\u2009\u2013\u200950. https:\/\/doi.org\/10.1016\/j.ijsu.2018.03.034","DOI":"10.1016\/j.ijsu.2018.03.034"},{"issue":"5","key":"733_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.4103\/jcrt.JCRT_1040_19","volume":"16","author":"M Li","year":"2020","unstructured":"Li M, Qin Y, Mei A, Wang C, Fan L. Effectiveness of radiofrequency ablation therapy for patients with unresected stage IA non-small cell lung cancer. J Cancer Res Ther. 2020;16(5):1007\u201313. https:\/\/doi.org\/10.4103\/jcrt.JCRT_1040_19","journal-title":"J Cancer Res Ther"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-024-00733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-024-00733-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-024-00733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T08:06:56Z","timestamp":1720685216000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-024-00733-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1186\/s40644-024-00733-4","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"1 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because this study analyzed secondary data from the publicly accessible database, no patients were involved directly. The study was approved by the local Ethics Committee and Institutional Review Board to use de-identified data, including patient clinicopathological features, tumor histology, tumor size, timing, and type of the first course treatment, and outcomes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}